Weight‑loss medications and group health insurance: What’s covered and how to qualify

Obesity affects more than 26% of Canadian adults and has been recognized as a chronic disease by the Canadian Medical Association since 2015. As demand for effective weight loss treatments continues to grow, medications like Ozempic and Wegovy have surged in popularity.

However, access to these drugs remains inconsistent across Canada, largely due to differences in coverage across public health plans, private insurance, and employer-sponsored group benefits.

Quick Answer: Are weight-loss medications covered in Canada?

Weight loss medications are generally not covered under public health plans in Canada. Drugs like Wegovy and Contrave are excluded, while GLP-1 medications such as Ozempic and Mounjaro are typically covered only for type 2 diabetes, not for weight loss. 

Some group insurance plans may cover weight loss medications, but access depends on the specific plan design, insurer policies, and medical eligibility criteria. Personal health insurance plans, on the other hand, rarely include coverage for weight loss medications and often exclude them altogether.

Common medications used for weight loss and their coverage in Canada

Several medications are used for weight management in Canada, but not all are specifically approved for weight loss, and insurance coverage remains limited and highly conditional.

Approved for weight loss

These medications are approved by Health Canada specifically for weight management, but coverage is still limited and usually requires prior authorization.

• Wegovy (semaglutide 2.4 mg): Approved for chronic weight management. Coverage is gradually emerging in select group plans, but typically requires strict eligibility criteria such as BMI thresholds.
• Saxenda (liraglutide): Approved for weight loss. May be covered under some group plans, but availability is limited and often subject to medical review and approval.
• Contrave (naltrexone/bupropion): Approved for weight management. Coverage may be available under select plans but usually requires prior authorization.
• Orlistat: Approved for weight loss and available over the counter, but not typically covered by insurance due to lower cost and less clinical effectiveness.

Primarily approved for diabetes (used off-label for weight loss)

These medications are approved for type 2 diabetes but are often prescribed off-label for weight loss. Insurance coverage is generally limited to their approved use.

• Ozempic (semaglutide 1mg): Approved for type 2 diabetes. Most insurers cover it only for diabetes, not for weight loss. Exceptions may be made for weight-related comorbidities under strict criteria.
• Mounjaro (tirzepatide): Approved for diabetes, not weight loss. Covered for diabetes only. Off-label use for weight loss is not typically reimbursed.
• Rybelsus (oral semaglutide): Approved for diabetes. Coverage is limited to diabetic use and may not extend to weight loss.

How much do these weight loss medications cost in Canada?

Weight loss medications in Canada can be expensive, especially without insurance coverage. Here’s an approximate monthly cost for some common weight loss medications:

• Ozempic: $200–$300 per month
• Wegovy: $400–$570 per month
• Mounjaro: $300–$4500 per month
• Saxenda: $450–$600 per month

In many cases, annual costs can exceed $3,000–$7,000 per year depending on the medication and dosage. This is why insurance coverage (when available) can make a significant difference.

Approval requirements for weight loss medications under group insurance

Even when group health insurance plans in Canada cover weight loss medications, access is typically subject to a formal approval process. Most insurers require the following:

• Prior authorization: A pre-approval process where the insurer reviews your medical information before agreeing to cover the medication
• Proof of medical necessity: Documentation from a healthcare provider confirming that the treatment is essential for your health
• BMI thresholds or comorbidities: Medical evidence showing a patient has a high BMI (typically 30+) or related health conditions like diabetes or hypertension
• Step therapy: A cost-control measure requiring patients to try lower-cost or first-line treatments before approving newer or more expensive drugs

Why aren’t weight loss medications widely covered in Canada?

Despite surging demand, coverage for GLP-1 drugs like Ozempic and Wegovy remains limited across provincial plans and private group benefits.

Key barriers include:

• High costs and insurer risk: Annual prices exceed $5,000 per patient (e.g., Wegovy at ~$450/month), straining small group plans where premiums could rise 10-20% with broad adoption.
• Need for lifelong therapy: Studies show 70-80% of weight regain within a year of stopping, making indefinite coverage unsustainable without proven endpoints.
• Off-label prescribing: Ozempic’s diabetes-only federal approval leads provinces like BC and Ontario to restrict it for obesity; private insurers require BMI ≥30 + comorbidities.
• Supply shortages and rapid uptake: 2024-2026 shortages prompted CADTH to deprioritize obesity drugs for public formularies, while private plans cap approvals to control 25%+ demand spikes.

Insurers like Green Shield and Sun Life now enforce rigorous criteria (e.g., supervised diet/exercise failure + specialist referral) leaving many patients to pay out-of-pocket or via health spending accounts in small business plans.

Common reasons coverage gets denied

Many weight‑loss medication claims are rejected because they don’t match the insurer’s specific clinical and administrative rules. Key reasons include:

• No prior authorization: Most group and private plans require pre‑approval for GLP‑1 drugs and other obesity medications; claims submitted without a completed PA are routinely denied, even if the drug is listed as “eligible.”
• BMI or medical criteria not met: Insurers often require a minimum BMI threshold (e.g., ≥30, or ≥27 with comorbidities like diabetes, hypertension, or sleep apnea), plus documented failed attempts at lifestyle‑based or lower‑cost interventions.
• Prescription for off‑label use: Drugs such as Ozempic (semaglutide) are approved in Canada for type 2 diabetes, not obesity; prescribing them solely for weight loss without an approved obesity indication can lead to denial.
• Step therapy requirements not followed: Many plans require patients to first try and fail lower‑cost options (e.g., GLP‑1s at lower doses, or traditional diabetes/weight‑loss agents) before approving higher‑cost drugs; skipping these steps triggers rejection.
• Missing documentation from a healthcare provider: Insurers increasingly demand detailed clinical notes showing diagnosis of obesity, duration of obesity‑related conditions, attempts at diet/exercise or programs, and a clear treatment plan; incomplete or vague forms and missing provider signatures are common causes of denial.

Which Canadian insurance companies cover weight loss medications?

Coverage for weight loss medications can vary significantly between insurers, as most decisions depend on the specific group plan design and employer-selected benefits. Here’s how some of the biggest Canadian insurers approach coverage:

• Manulife: May cover Wegovy in some plans; Ozempic typically only for diabetes
• Canada Life: Customizable plans; requires prior authorization
• Blue Cross: Coverage varies by employer; weight-loss drugs optional
• GreenShield: May include coverage with strict criteria
• Sun Life: Offers optional coverage; usually tied to diabetes treatment